BTNL9

Across TCGA pan-cancer cohorts, BTNL9 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of BTNL9’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where BTNL9 RNA is repressed in tumor relative to normal tissue. In most cancer types BTNL9 is over-expressed in tumor, although a few such as LUAD and BLCA show the opposite, repressed pattern.

LUAD, BLCA, and LUSC are the cancer types where BTNL9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTNL9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−4.068	<.001	11	view →
BLCA	All	All	−1.206	<.001	11	view →
LUSC	Female	II,III,IV	−3.947	<.001	9	view →
KIRC	Female	All	+1.874	<.001	9	view →
KIRP	Male	II,III,IV	−1.800	<.001	9	view →
COAD	Female	II,III,IV	+1.085	<.001	8	view →
LIHC	All	II,III,IV	+0.872	<.001	8	view →
BRCA	All	II,III,IV	−3.603	<.001	6	view →
THCA	All	IV	−1.997	.002	3	view →
UCEC	All	All	−1.416	<.001	2	view →
CHOL	Male	All	−0.865	.003	2	view →
STAD	Male	All	+0.552	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

BTNL9–LUAD

Open the LUAD breakdown →